Share this to:

Support & Insight for the Autumn of Life

Can Targacept Beat Aricept?

Targacept logoTargacept is taking a confident approach in its latest clinical trial. Rather than pitting their new Alzheimer’s drug against a placebo, they are putting it head-to-head against today’s most successful Alzheimer’s-fighting medication. Learn about the launch of The Targacept TC-1734 Clinical Trial.

WINSTON-SALEM, N.C.–Targacept, Inc. a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, announced that it has completed recruitment of patients in the Phase 2b study of TC-1734 as a treatment for mild to moderate Alzheimer’s disease.

The ongoing Phase 2b study is a double blind, randomized, parallel group trial evaluating Targacept TC-1734 head-to-head against donepezil (which is marketed under the familiar brand name Aricept®). Donepezil is currently the medication most often prescribed for Alzheimer’s disease.

“While the pursuit of an effective new treatment for Alzheimer’s disease has been historically challenging, the unmet medical need is both enormous and growing,” said Dr. Stephen A. Hill, Targacept’s President and Chief Executive Officer. “Our thanks go to the patients, study sites and investigators who are collaborating with us in the effort to find a new medicine for this devastating disease.”

The study, designed to randomize approximately 300 patients, is being conducted at sites predominantly in Eastern Europe and also in the United States.

The Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-Cog) and the Clinician Interview-Based Impression of Change Plus Caregiver Input (CIBIC-(+)) are co-primary endpoints of the study, with the Alzheimer’s Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) replacing CIBIC-(+) as a co-primary endpoint for European regulatory purposes. The study includes a 3-week screening period, followed by a 12-month treatment period during which patients receive a fixed dose of TC-1734 (30mg) or donepezil once daily.

Targacept expects to report top-line results from the study in mid-2014. TC-1734 is a modulator of the alpha4beta2 neuronal nicotinic receptor subtype.


Evidence of Efficacy for TC-1734 (AZD3480) in the Treatment of Cognitive Impairment in Older Subjects

About Targacept

Targacept is developing a diverse pipeline of innovative NNR Therapeutics™ for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, unique proteins that regulate vital biological functions that are impaired in various disease states. Targacept’s clinical pipeline includes multiple Phase 2 product candidates, all representing first-in-class opportunities. Targacept leverages its scientific leadership and diverse pipeline to attract significant collaborations with global pharmaceutical companies. For more information, please visit

TARGACEPT: Building Health, Restoring Independence®

Notify of

Inline Feedbacks
View all comments
B. Berger

B. Berger

Visit Our Pages On:


This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chaffe, the important articles & videos from each week’s river of news. With a new post on Alzheimer’s or dementia appearing on the internet every 7 minutes, the site’s focus on the best information has been a help to many over the past 15 years. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor


person wearing hearing aid
Can Hearing Aids Diminish Dementia?
Hearing loss and dementia may be linked, but there is a silver lining here.
Black tweezers on white background.
CLR01 Beats Curcumin in Blocking Alzheimer's
CLR01, a "molecular tweezer", keeps brain proteins from the clumping, or aggregating, that causes Alzheimer's, Parkin...
Researching the Brain
Gene Allele DR4 Fends off Alzheimer's AND Parkinson's
"The night after we found that out, I couldn’t sleep," said Senior Researcher Dr. Emmanuel Mignot. 1 in 5 people have...
Would love your thoughts, please comment.x
News, Treatments, Care Tips

Subscribe To The Weekly Newsletter

videos & articles on Research & Prevention
News to Get at the Truth

Subscribe To Our Weekly Newsletter